Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies (vol 74, pg 1216, 2017)

被引：1
|
作者：
Kao, J. C.
Liao, B.
Markovic, S. N.
机构：
来源：
JAMA NEUROLOGY | 2017年 / 74卷 / 10期
关键词：
D O I：
10.1001/jamaneurol.2017.3044
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1271 / 1271
页数：1
相关论文
共 50 条
  • [1] Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies
    Kao, Justin C.
    Liao, Bing
    Markovic, Svetomir N.
    Klein, Christopher J.
    Naddaf, Elie
    Staff, Nathan P.
    Liewluck, Teerin
    Hammack, Julie E.
    Sandroni, Paola
    Finnes, Heidi
    Mauermann, Michelle L.
    [J]. JAMA NEUROLOGY, 2017, 74 (10) : 1216 - 1222
  • [2] Neurological complications of anti-programmed death 1 antibodies
    Kao JC
    Liao B
    Markovic SN
    [J]. 中华物理医学与康复杂志, 2017, 39 (12) : 892 - 892
  • [3] Anti-Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?
    Marchand, Lucien
    Thivolet, Arnaud
    Saintigny, Pierre
    Fabien, Nicole
    Vouillarmet, Julien
    Thivolet, Charles
    [J]. DIABETES CARE, 2018, 41 (03) : 638 - 639
  • [4] Impact of radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
    Samuel, E.
    So, Y. J.
    Hiong, A.
    Balasubramanian, A.
    Parakh, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma
    Metcalfe, Whitney
    Anderson, Jaime
    Van Anh Trinh
    Hwu, Wen-Jen
    [J]. DISCOVERY MEDICINE, 2015, 19 (106) : 393 - 401
  • [6] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [7] Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
    Kataoka, Hiroshi
    Shimada, Daisuke
    Nanaura, Hitoki
    Sugie, Kazuma
    [J]. OXFORD MEDICAL CASE REPORTS, 2021, (09): : 330 - 332
  • [8] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma - A Clinical Update
    Van Anh Trinh
    Joseph, Jocelyn
    Hwu, Wen-Jen
    [J]. DISCOVERY MEDICINE, 2018, 25 (135) : 31 - 40
  • [9] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy (vol 35, pg 709, 2017)
    Naidoo
    Long, Georgina
    Hellmann, Matthew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) : 2590 - 2590
  • [10] When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
    Lauren B. Banks
    Ryan J. Sullivan
    [J]. American Journal of Clinical Dermatology, 2020, 21 : 313 - 321
12345